The effect of duration of follow-up and presence of competing risk on lifespan-gain from implantable cardioverter defibrillator therapy: who benefits the most?
2015; Oxford University Press; Volume: 36; Issue: 26 Linguagem: Inglês
10.1093/eurheartj/ehv102
ISSN1522-9645
AutoresClaire E. Raphael, Judith A. Finegold, Anthony Barron, Zachary I. Whinnett, Jamil Mayet, Cecilia Linde, John G.F. Cleland, Wayne C. Levy, Dárrel P. Francis,
Tópico(s)Cardiomyopathy and Myosin Studies
ResumoBackgroundIn at-risk patients with left ventricular dysfunction, implantable cardioverter defibrillators (ICDs) prolong life. Implantable cardioverter defibrillators are increasingly implanted for primary prevention and therefore into lower risk patients. Trial data have demonstrated the benefit of these devices but does not provide an estimate of potential lifespan-gain over longer time periods, e.g. a patient's lifespan.
Referência(s)